Tag: AstraZeneca Plc (AZN)

TapImmune and Loxo Oncology Have Interesting News

TapImmune and Loxo Oncology Have Interesting News

The AACR 2016 meeting presentations differed substantially from previous meetings. The  2016 meeting has brought near certainty that, indeed, defeating cancer is a reachable objective. The road is lengthy, but the speed in analyzing the data and acting upon them towards improvement is unprecedented. You will find the most important information about the AACR cancer meeting in the upcoming Prohost Letter. In the NEWS TAPIMMUNE …
Prohost Letter #393

Prohost Letter #393

Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer immunotherapy. We remind that in the Prohost Letter issue #391, we dealt with the immunotherapy based on genetically engineered T Cells, enabling them to seek out, attack and neutralize cancer cells. The immune system’s T …
Breakthrough Drugs of the Week

Breakthrough Drugs of the Week

Recent Breakthrough Designated Products CANCER Acute Myeloid Leukemia PKC412 (midostaurin) developed by Novartis AG (NVS) is an oral, multi-targeted kinase inhibitor for acute myeloid leukemia (AML) with FLT3 mutations. It is also being studied for aggressive systemic mastocytosis/mast cell leukemia. FMS-like tyrosine kinase-3 (FLT3) is a cell-surface receptor for tyrosine kinase, which has a role in the upsurge of certain blood cell types. The drug has positive data …
Prohost Letter #390

Prohost Letter #390

Prohost Letter #390 COMPANIES USING CRISPR GENE EDITING TOOLS - The Firms Launched with CRISPR Patents Either Pending or Disputed! What Does This Mean? What are these Firms’ Priorities? But First: A Reminder In the last issue, Prohost #389, we pinpointed the gene editing technologies and techniques and demonstrated the difference between gene editing, which is genetic engineering, i.e., making changes in the genes themselves, and antisense …
Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination

Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination

In The NEWS IMMUNOTHERAPY MIRATI THERAPEUTICS Mirati Therapeutics (MRTX) is an oncology company focusing on genetic and epigenetic drivers of cancer. The firm’s clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, which is in Phase 1 clinical …
Prohost Letter #375 Part 1

Prohost Letter #375 Part 1

Prohost Letter #375 Part 1 BIOTECHNOLOGY: THE BEGINNING OF A NEW ERA STATE- OF-THE-ART APPROACHES FOR THE MANAGEMENT OF CHRONIC AND DEADLY DISEASES ARE IN HUMAN CLINICAL TRIALS We are encouraged by some novel treatments for chronic diseases and cancer and we are optimistic about results coming from their early- and late-phase trials. Picking advanced therapeutics is the magic word Sesame in the formula “Open Sesame”, which, …